<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02360371</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00047423</org_study_id>
    <secondary_id>R01DA035246-01A1</secondary_id>
    <nct_id>NCT02360371</nct_id>
  </id_info>
  <brief_title>A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans</brief_title>
  <official_title>A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Within-subject, double-blind, placebo-controlled examination of opioid abuse potential in&#xD;
      healthy individuals as a function of A118G SNP on the OPRM1 gene.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants completed a 5-day, within-subject, double-blind, placebo-controlled, randomized,&#xD;
      human laboratory abuse potential trial. Healthy individuals were admitted to a residential&#xD;
      research unit for 5 consecutive days. Blood samples were drawn for genome wide analyses using&#xD;
      the Global Screening Array on day 1. Participants were administered an oral dose of the&#xD;
      opioid hydromorphone (4mg) on day 2 of the study. Persons who did not evidence strong agonist&#xD;
      effects then proceeded into the randomized period wherein they received 0mg, 2mg, and 8mg of&#xD;
      oral hydromorphone on the remaining three study days. The order of dosing was randomized,&#xD;
      with only 1 dose administered per day and all participants receiving 1 exposure to each dose.&#xD;
      Outcomes were standard human abuse potential metrics, including self-reported drug effects&#xD;
      and feeling high. Data were analyzed as a function of the A118SNP on the OPRM1 gene that&#xD;
      codes for the mu opioid receptor. The overall aim was to determine whether signal for abuse&#xD;
      potential among persons with no history of opioid misuse was associated with genotype.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">May 2021</completion_date>
  <primary_completion_date type="Actual">May 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Within-subject, double-blind, randomized, placebo-controlled, human laboratory design wherein each participant completed each of the study conditions (outlined below as four arms). Participants were genotyped for rs-1799971and data were analyzed using between-group designs based upon rs-1799971 status.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Neither participants nor staff were informed of the class of drugs under investigation. Strict blinding was maintained.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Self-report Visual Analog Ratings of HIGH</measure>
    <time_frame>30 minutes after study drug administration</time_frame>
    <description>Peak visual analog rating scale values of HIGH (rated on 0-100 scale with higher scores indicating higher feeling of being HIGH) collected at 30 minute intervals post-drug administration for 6 hours.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-report Visual Analog Ratings of DRUG EFFECT</measure>
    <time_frame>30 minutes after study drug administration</time_frame>
    <description>Peak visual analog rating scale values of DRUG EFFECT (rated on 0-100 scale with higher scores indicating higher drug effect) collected at 30 minute intervals post-drug administration for 6 hours.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Opioid Sensitivity</condition>
  <condition>Individual Difference</condition>
  <condition>Abuse Opioids</condition>
  <arm_group>
    <arm_group_label>Placebo (oral)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Within-subject double-blind, administration of placebo oral capsule. Order of dose randomized session days 3-5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydromorphone (oral) 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within-subject double-blind, administration of hydromorphone via oral capsule. Order of dose randomized session days 3-5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydromorphone (oral) 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydromorphone oral capsule administered in double-blind manner on Day 2 as first study drug administration. Hydromorphone 4mg dosing day was set for safety purposes and non-randomized.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydromorphone (oral) 8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within-subject double-blind, administration of hydromorphone via oral capsule. Order of dose randomized session days 3-5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Within-subject test of blinded study medication</intervention_name>
    <description>Within-subject double-blind, randomized, placebo-controlled, residential human abuse potential study. All participants received 4mg oral hydromorphone on study day 2 and a subset continued into the randomized portion for study days 3-5 wherein they received placebo, 2mg hydromorphone, and 8mg hydromorphone in randomized order. Only one dose was administered per day and following randomized all participants received each dose in random order. Outcomes were collected during 8-hour residential-based sessions and included metrics of FDA human abuse potential testing as well as secondary outcomes of laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition. Participants were genotyped for rs-1799971 status and results were analyzed as between-group comparisons based upon genotype.</description>
    <arm_group_label>Hydromorphone (oral) 2mg</arm_group_label>
    <arm_group_label>Hydromorphone (oral) 4mg</arm_group_label>
    <arm_group_label>Hydromorphone (oral) 8mg</arm_group_label>
    <arm_group_label>Placebo (oral)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criterion:&#xD;
&#xD;
          1. Provide a urine sample that tests negative for opioids, methadone, buprenorphine,&#xD;
             oxycodone, amphetamine, cocaine, and benzodiazepines&#xD;
&#xD;
          2. Negative ethanol breath test (0.000)&#xD;
&#xD;
          3. Aged 21-50&#xD;
&#xD;
          4. Deemed medically eligible to take hydromorphone&#xD;
&#xD;
        Exclusion Criterion:&#xD;
&#xD;
          1. Answer &quot;yes&quot; to question 1 of the Brief Pain Inventory (89) to assess the presence of&#xD;
             chronic pain.&#xD;
&#xD;
          2. Current use of opioids or other medications for pain&#xD;
&#xD;
          3. Meet DSM-5 criteria for current or lifetime alcohol or drug use disorder (excluding&#xD;
             nicotine)&#xD;
&#xD;
          4. Self-report any illicit drug use in the past 7 days&#xD;
&#xD;
          5. Self-report opioid use &gt;5 days in the past 30&#xD;
&#xD;
          6. Evidence of opioid physical dependence at screening or following 1st residential&#xD;
             overnight (following confirmed opioid abstinence)&#xD;
&#xD;
          7. Allergy to hydromorphone or other opioid agonists&#xD;
&#xD;
          8. Experience an adverse event that warrants opioid antagonist treatment following 1st&#xD;
             hydromorphone dose.&#xD;
&#xD;
          9. If female, not be pregnant or breastfeeding&#xD;
&#xD;
         10. Presence of any clinically significant medical (e.g., chronic renal insufficiency,&#xD;
             history of myocardial infarction, seizure disorder) and/or psychiatric illness (e.g.,&#xD;
             schizophrenia, bipolar disorder) that may interfere with study participation.&#xD;
&#xD;
         11. BMI &gt;30 (obese category)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly E Dunn, Ph.D., MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University Bayview Medical Campus</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>February 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2015</study_first_posted>
  <results_first_submitted>July 20, 2021</results_first_submitted>
  <results_first_submitted_qc>September 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 5, 2021</results_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>opioid</keyword>
  <keyword>abuse</keyword>
  <keyword>genetic</keyword>
  <keyword>A118G</keyword>
  <keyword>OPRM1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02360371/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02360371/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>100 participants were recruited from the community for participation. Analyses were based upon OPRM1 rs-1799971 allele status (A, G), which was available for 97 participants. All participants completed the same 4 study arms.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>A118G (rs1799971-G)</title>
          <description>This is a within-subject study wherein the same participants moved from one treatment arm to the next and results were analyzed posthoc as a function of genotype.</description>
        </group>
        <group group_id="P2">
          <title>A118A (rs1799971-A)</title>
          <description>This is a within-subject study wherein the same participants moved from one treatment arm to the next and results were analyzed posthoc as a function of genotype.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Placebo (Oral)</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Hydromorphone (Oral) 2mg</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Hydromorphone (Oral) 4mg</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Hydromorphone (Oral) 8mg</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="69"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A118G (rs1799971-G)</title>
          <description>This is a within-subject study wherein the same 100 participants moved from one treatment arm to the next.</description>
        </group>
        <group group_id="B2">
          <title>A118A (rs1799971-A)</title>
          <description>This is a within-subject study wherein the same 100 participants moved from one treatment arm to the next.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="84"/>
            <count group_id="B3" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.6" spread="10.0"/>
                    <measurement group_id="B2" value="33.3" spread="8.9"/>
                    <measurement group_id="B3" value="33.9" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Self-report Visual Analog Ratings of HIGH</title>
        <description>Peak visual analog rating scale values of HIGH (rated on 0-100 scale with higher scores indicating higher feeling of being HIGH) collected at 30 minute intervals post-drug administration for 6 hours.</description>
        <time_frame>30 minutes after study drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A118G (rs1799971-G)</title>
            <description>This is a within-subject study wherein the same 100 participants moved from one treatment arm to the next.</description>
          </group>
          <group group_id="O2">
            <title>A118A (rs1799971-A)</title>
            <description>This is a within-subject study wherein the same 100 participants moved from one treatment arm to the next.</description>
          </group>
        </group_list>
        <measure>
          <title>Self-report Visual Analog Ratings of HIGH</title>
          <description>Peak visual analog rating scale values of HIGH (rated on 0-100 scale with higher scores indicating higher feeling of being HIGH) collected at 30 minute intervals post-drug administration for 6 hours.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo (oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="13.2"/>
                    <measurement group_id="O2" value="6.6" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hydromorphone (oral) 2mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="5.9"/>
                    <measurement group_id="O2" value="5.6" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hydromorphone (oral) 4mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="19.8"/>
                    <measurement group_id="O2" value="18.4" spread="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hydromorphone (oral) 8mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" spread="29.7"/>
                    <measurement group_id="O2" value="22.5" spread="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.567</p_value>
            <method>Mixed methods</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Self-report Visual Analog Ratings of DRUG EFFECT</title>
        <description>Peak visual analog rating scale values of DRUG EFFECT (rated on 0-100 scale with higher scores indicating higher drug effect) collected at 30 minute intervals post-drug administration for 6 hours.</description>
        <time_frame>30 minutes after study drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A118G (rs1799971-G)</title>
            <description>This is a within-subject study wherein the same participants moved from one treatment arm to the next and results were analyzed posthoc as a function of genotype.</description>
          </group>
          <group group_id="O2">
            <title>A118A (rs1799971-A)</title>
            <description>This is a within-subject study wherein the same participants moved from one treatment arm to the next and results were analyzed posthoc as a function of genotype.</description>
          </group>
        </group_list>
        <measure>
          <title>Self-report Visual Analog Ratings of DRUG EFFECT</title>
          <description>Peak visual analog rating scale values of DRUG EFFECT (rated on 0-100 scale with higher scores indicating higher drug effect) collected at 30 minute intervals post-drug administration for 6 hours.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Placebo (oral)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="21.3"/>
                    <measurement group_id="O2" value="11.1" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hydromorphone (oral) 2mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="16.5"/>
                    <measurement group_id="O2" value="11.0" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hydromorphone (oral) 4mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.6" spread="27.0"/>
                    <measurement group_id="O2" value="31.9" spread="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hydromorphone (oral) 8mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" spread="37.3"/>
                    <measurement group_id="O2" value="39.5" spread="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.805</p_value>
            <method>Mixed Model</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected for 6 hours post each drug administration session. Only adverse events (AEs) judged to be possibly, probably, or definitely related to study participation are reported.</time_frame>
      <desc>AEs were documented the end of each session or in response to spontaneous reporting from participants, as a function of dose but not allele status, during the session. AEs were queried by asking &quot;are you experiencing any side effects of the study medication?&quot; The 4mg hydromorphone dose was the safety test dose and all individuals who had strong agonist responses (e.g., vomiting) in response to that dose were discontinued; therefore more individuals received 4mg than did other doses.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Oral)</title>
          <description>Within-subject double-blind, administration of placebo oral capsule. Order of dose randomized session days 3-5.</description>
        </group>
        <group group_id="E2">
          <title>Hydromorphone (Oral) 2mg</title>
          <description>Within-subject double-blind, administration of hydromorphone via oral capsule. Order of dose randomized session days 3-5.</description>
        </group>
        <group group_id="E3">
          <title>Hydromorphone (Oral) 4mg</title>
          <description>Hydromorphone oral capsule administered in double-blind manner on Day 2 as first study drug administration. Hydromorphone 4mg dosing day was set for safety purposes and non-randomized.</description>
        </group>
        <group group_id="E4">
          <title>Hydromorphone (Oral) 8mg</title>
          <description>Within-subject double-blind, administration of hydromorphone via oral capsule. Order of dose randomized session days 3-5.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="82"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="97"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="16" subjects_affected="14" subjects_at_risk="97"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" events="39" subjects_affected="29" subjects_at_risk="97"/>
                <counts group_id="E4" events="29" subjects_affected="18" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="82"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Dry Mouth (Xerostomia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="97"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="17" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="82"/>
                <counts group_id="E3" events="48" subjects_affected="31" subjects_at_risk="97"/>
                <counts group_id="E4" events="35" subjects_affected="20" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Euphoria/High</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Impaired, Groggy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Light Headedness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="97"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Shaky</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="97"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Sluggish</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Pruritus (Itching)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="82"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="82"/>
              </event>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kelly Dunn, Ph.D., MBA</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-550-2254</phone>
      <email>kdunn9@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

